Musatti L - Search Results

1

Plasma free fatty acids and serum insulin in subjects feeding at 12-hour intervals; effects of methionyl growth hormone and of acipimox, an inhibitor of lipolysis.

Pontiroli AE, Lanzi R, Monzani M, Musatti L, Guglielmone C, Pozza G. Pontiroli AE, et al. Among authors: musatti l. J Endocrinol Invest. 1992 Feb;15(2):85-91. doi: 10.1007/BF03348669. J Endocrinol Invest. 1992. PMID: 1569294 Clinical Trial.

2

Acipimox-induced facial skin flush: frequency, thermographic evaluation and relationship to plasma acipimox level.

Pontiroli AE, Fattor B, Pozza G, Pianezzola E, Strolin Benedetti M, Musatti L. Pontiroli AE, et al. Among authors: musatti l. Eur J Clin Pharmacol. 1992;43(2):145-8. doi: 10.1007/BF01740661. Eur J Clin Pharmacol. 1992. PMID: 1425871 Clinical Trial.

3

Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial.

Crepaldi G, Avogaro P, Descovich GC, Di Perri T, Postiglione A, Sirtori CR, Strano A, Ventura S, Musatti L. Crepaldi G, et al. Among authors: musatti l. Atherosclerosis. 1988 Mar;70(1-2):115-21. doi: 10.1016/0021-9150(88)90105-0. Atherosclerosis. 1988. PMID: 3281679 Clinical Trial.

4

Inhibition of lipolysis by nicotinic acid and by acipimox.

Fuccella LM, Goldaniga G, Lovisolo P, Maggi E, Musatti L, Mandelli V, Sirtori CR. Fuccella LM, et al. Among authors: musatti l. Clin Pharmacol Ther. 1980 Dec;28(6):790-5. doi: 10.1038/clpt.1980.236. Clin Pharmacol Ther. 1980. PMID: 7438693

5

Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis.

Sirtori CR, Gianfranceschi G, Sirtori M, Bernini F, Descovich G, Montaguti U, Fuccella LM, Musatti L. Sirtori CR, et al. Among authors: musatti l. Atherosclerosis. 1981 Feb-Mar;38(3-4):267-71. doi: 10.1016/0021-9150(81)90042-3. Atherosclerosis. 1981. PMID: 7225165 Clinical Trial.

6

Pharmacokinetics of acipimox and of its N-deoxy metabolite following single and repeated oral administration to healthy volunteers.

Efthymiopoulos C, Strolin Benedetti M, Poggesi I, Ruff F, Basileo G, Musatti L. Efthymiopoulos C, et al. Among authors: musatti l. Therapie. 1993 Jan-Feb;48(1):23-6. Therapie. 1993. PMID: 8356541

7

Acipimox stimulates skin blood flow by a cyclo-oxygenase-dependent mechanism.

Edlund A, Musatti L, Wennmalm A. Edlund A, et al. Among authors: musatti l. Eur J Clin Pharmacol. 1990;39(1):37-41. doi: 10.1007/BF02657054. Eur J Clin Pharmacol. 1990. PMID: 2125938 Clinical Trial.

8

Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent.

Musatti L, Maggi E, Moro E, Valzelli G, Tamassia V. Musatti L, et al. J Int Med Res. 1981;9(5):381-6. doi: 10.1177/030006058100900515. J Int Med Res. 1981. PMID: 7028536 Clinical Trial.

9

Treatment of macroprolactinoma with cabergoline: a study of 85 patients.

Ferrari CI, Abs R, Bevan JS, Brabant G, Ciccarelli E, Motta T, Mucci M, Muratori M, Musatti L, Verbessem G, Scanlon MF. Ferrari CI, et al. Among authors: musatti l. Clin Endocrinol (Oxf). 1997 Apr;46(4):409-13. doi: 10.1046/j.1365-2265.1997.1300952.x. Clin Endocrinol (Oxf). 1997. PMID: 9196602

10

Pregnancy outcome after treatment with the ergot derivative, cabergoline.

Robert E, Musatti L, Piscitelli G, Ferrari CI. Robert E, et al. Among authors: musatti l. Reprod Toxicol. 1996 Jul-Aug;10(4):333-7. doi: 10.1016/0890-6238(96)00063-9. Reprod Toxicol. 1996. PMID: 8829257

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters